Emergex vaccines, a company with the goal of offering affordable, practical and effective vaccines on-demand, are pleased to announce they have been awarded a £499,825 grant from Innovate UK, the UKs innovation agency. Grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programs.
Professor Thomas Rademacher, CEO, commented “Emergex has a grand vision to create a socially responsible company that will address the critical global need to have affordable and effective vaccines against emerging viral and bacterial outbreaks. By creating an International Repositories of vaccines that can be used at the start of epidemics we can potentially protect populations at the time of utmost need. This will also allow for field testing of human specific T cell vaccines in relevant clinical situations. The support from Innovate UK allows us to advance our Zika and Filovirus vaccine programs as quickly as possible.”
For more detail on the award please see the Innovate UK announcement (Pg 11):